Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT02884310 |
| Other study ID # |
ErasmeUH P2012/20 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
Phase 4
|
| First received |
August 18, 2016 |
| Last updated |
August 17, 2017 |
| Start date |
January 2013 |
| Est. completion date |
May 2016 |
Study information
| Verified date |
August 2017 |
| Source |
Erasme University Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Individually-tailored administration of the opioid analgesic component during general
anaesthesia is still a challenge for the anesthesiologist. The aim of this protocol is to
look if the gradient response of a nociception index to a calibrated tetanic stimulus during
standard anesthetic conditions, could help to titrate remifentanil analgesia before tracheal
intubation and before skin incision. The studied parameters are the SPI index developed by
General Electric, the "Analgesia Nociception Index" and the pupil dilation using the pupil
scan algometer.
Description:
Two randomized groups of patients scheduled for general surgery under Target Controlled
remifentanil propofol anaesthesia are compared.
All patients receive two standard calibration tests (Tetanic stimulus at the ulnar nerve: 100
Hertz, 60 milliamperes, 30 seconds) before tracheal intubation and skin incision at a stable
remifentanil level of 3 ng/ml. Propofol concentration is targeted to maintain the BIS value
as close as possible to 50. Patients are mechanically ventilated at an inspired O2
concentration of 50% and using tidal volumes of 8 to 10 mL/kg and respiratory rates of 12 to
15/min. Patients receive an induction dose of neuromuscular blocking agent.
In the treated group, the importance of the Surgical Plethysmogram Index (SPI) gradient after
the tetanic stimulus will guide the subsequent administration of remifentanil to cover
tracheal intubation and surgical incision. As compared to SPI value before the calibration
test, a less than 10 unit increase in SPI will not prompt any change in remifentanil
concentration before tracheal intubation and surgical incision. An increase in SPI between 10
and 20 units will prompt a remifentanil effect-site target concentration of 4 ng/ml, between
20 and 30 of 5 ng/ml, and above 30 of 6 ng/ml for tracheal intubation. Once the trachea is
intubated, remifentanil concentration will be lowered to 3 ng /ml. It will be adjusted again
before surgical incision according to the same criteria. Ten minutes after surgical incision
until the end of the surgical procedure, the remifentanil concentration will be targeted to
maintain SPI between 20 and 50.
In the control group, conditions will be the same as those of first group, except that
remifentanil concentration will be adjusted according to heart rate and blood pressure. The
anesthesiologist in charge is blinded to the results of the SPI gradient after the two
calibration tests at 3 ng/ml remifentanil concentration and also blinded to the 2 other
nociception indexes at all times. Remifentanil concentration is targeted at 4 ng/ml before
tracheal intubation and surgical incision. Ten minutes after skin incision until the end of
surgery, remifentanil concentrations will be adjusted according to the hemodynamic
parameters.
Data acquisition and analysis will lead to the following statistical comparisons between the
two groups:
- Hemodynamic reactivity to tracheal intubation and surgical incision.
- Concordance between SPI, Analgesia Nociception Index (ANI), and pupil diameter
variations in response to the calibration test and during maintenance of anesthesia.
- Reliability of the prediction of hemodynamic reactivity to intubation and incision by
the SPI, ANI, pupil diameter and hemodynamic response to the calibration test, and
improvement of the prediction when combining the information given by those parameters.
2.2. Monitoring The monitoring will correspond to the classical monitoring of any general
anesthesia procedures (Electrocardiogram, peripheral saturation in O2, Non-Invasive Blood
Pressure, respiratory gases, pressure and flows in the airway, muscle relaxation).
The following parameters will be continuously recorded and saved for subsequent analysis :
- Heart rate
- Inspired and expired gases : O2, Carbon dioxide (CO2)
- Spirometry : peak, plateau, and end-expiratory pressures
- EKG : heart rate
- Non-invasive blood pressure : automatic measured every 5 minutes
- SPI
Additional monitoring :
- Bispectral Index (BIS)
- ANI
- Pupil dilation measurement
2.3. Anesthetic medications
2.3.1. Premedication The premedication will consist of 0.5 mg oral alprazolam (XANAX) one
hour before induction of anesthesia.
2.3.2. Anesthesia General anesthesia will be induced and maintained using Target Controlled
Infusions (TCI) of propofol and remifentanil, and using a single cisatracurium bolus.
2.3.2.1. Induction of anesthesia In the experimental group, the initial target effect-site
concentration (Ce) of remifentanil will be 3 ng/ml and 3 µg/ml for propofol. The propofol Ce
will be increased by steps of 1 µg/ml until loss of consciousness (6.0 µg/ml maximum). A 0.2
mg/kg bolus of cisatracurium will be given immediately after loss of consciousness. The
tetanic calibration test will be performed once all responses to train of four (TOF)
stimulation have disappeared. The BIS target before the tetanic stimulation will be 50 (range
40-60).
Pupil dilation and the ANI response to the tetanic stimulation will also be measured.
After tracheal intubation, remifentanil concentration will be reduced to 3 ng/ml, and
propofol concentration adjusted to keep the BIS value as close to 50 as possible.
In the control group, the induction of anesthesia will occur the same way as in the
experimental group, except that the initial concentration of remifentanil will be 3 ng/ml,
and 4 ng/ml for tracheal intubation and incision. It will be changed according to hemodynamic
parameters thereafter. Propofol concentration will be targeted to maintain stable BIS values
around 50. The tetanic calibration test will be performed blindly once all responses to TOF
stimulation have disappeared, and once propofol and remifentanil concentrations have been
stable for more than 5 minutes. SPI, ANI, and pupil diameter values will be blindly recorded.
2.3.2.2. Maintenance of anesthesia The upper and lower limits of propofol concentrations will
be 2.0 and 6.0 µg/ml, respectively. It will be targeted to maintain a stable BIS value around
50. During surgery, remifentanil concentrations will range between 2.0 and 10 ng/ml. In the
experimental group (SPI), the calibration test-defined remifentanil concentration and the
pre-incision propofol concentration will be kept intact for 10 minutes after the surgical
incision. Thereafter, they will be modified according to the below-defined criteria.
In the control group, remifentanil concentration will be maintained at 4 ng/ml during 10
minutes after the surgical incision. Thereafter, propofol and remifentanil concentrations
will be modified according to hemodynamic reactivity, and according to BIS, which will be
kept at 50 (see tables below). SPI, and the other nociception indexes will be blindly
recorded in that group.
2.3.2.3. Propofol concentration adaptations in both groups Propofol concentrations will be
adapted to maintain BIS as close to 50 as possible. Changes in propofol concentration will be
allowed every 5 minutes after having reached the new target, if necessary, as a function of
criteria defined in Table 2.
Table 2 Propofol concentration adaptation as a function of BIS BIS Change in propofol
concentration >70 +2 µg/ml > 55 +1 µg/ml < 45 -0.5 µg/ml < 35 -1 µg/ml
2.3.2.4. Remifentanil concentration adaptations
2.3.2.4.1. In the experimental group The goal in the experimental group will be to maintain a
SPI value between 20 and 40 during surgery, from 10 minutes after incision to the end.
After incision, remifentanil concentration will be adapted according to criteria defined in
Table 3.
Table 3 Remifentanil concentration adaptation during surgery (range 2 to 10 ng/ml) Event
Change in remifentanil concentration SPI<20 -1 ng/ml SPI>50 +1 ng/ml SPI>80 +2 ng/ml
In case of hemodynamic reactivity (increase or decrease of more than 20 % as compared to
reference values), despite adequate adaptation of remifentanil concentration as a function of
SPI, it will be corrected according to criteria defined in paragraph 2.5 for hypotension or
bradycardia episodes. In case of hypertension, (more than 20% as compared to reference
value), despite adequate remifentanil concentration adaptation as a function of SPI, 0.5 mg
intravenous boluses of nicardipine (Nicardipine) will be administered intravenously until
return to acceptable values. Similarly, in case of tachycardia despite adequate adaptation of
remifentanil adaptation as a function of SPI values, it will be corrected by 1 mg intravenous
boluses of metoprolol (Seloken) until return to pre-defined values. In the event of both
cases, exclusion of the patient's data from statistical analysis should be considered.
2.3.2.4.2. In the control group Before surgical incision, in the absence of hemodynamic
reactivity, remifentanil concentration will be 4 ng/ml, and will not change for 10 minutes
after incision.
Ten minutes after incision, remifentanil concentration will be adapted according to
hemodynamic reactivity
Table 4 Remifentanil concentration adaptation in the Control group Hemodynamic Reactivity (>
20% as compared to reference values or Mean Arterial Pressure (MAP) > 90 mmHg and/or Heart
Rate (HR) > 100/min): -1 ng/ml Hypotension/bradycardia (<20% as compared to reference values
or MAP < 60 mmHg and/or HR < 45/min): +1 ng/ml
Remifentanil concentration will always be kept between 2 and 10 ng/ml. In case of hemodynamic
changes at those concentrations, they will be corrected according to the criteria defined
above for the SPI group.
